NCT05305027

Brief Summary

Early diagnosis of pregnancy with its localization and evolution has always been one of the major objectives of gynecology and obstetrics, even more so in Artificial Reproductive Technology (ART) centers. The pivotal test is the βHCG assay. Various protocols have been proposed over the years, including single assessment and serial assays. Several studies in the past years have tried to define a cut-off predictive of a successful pregnancy. Abnormal levels of βHCG are associated with biochemical pregnancies, non-viable pregnancies and ectopic pregnancies (EP). The efficacy of a single serum βHCG test to predict EP is low and a significant amount of time and resources are spent diagnosing it. In recent studies, better sensitivity was obtained from the ratio of two successive time points of βHCG concentration, with better specificity instead from regression models. These proposed models however lack validation and require further improvement.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2011

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2011

Completed
10 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2020

Completed
1.1 years until next milestone

First Submitted

Initial submission to the registry

February 3, 2022

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 31, 2022

Completed
Last Updated

March 31, 2022

Status Verified

March 1, 2022

Enrollment Period

10 years

First QC Date

February 3, 2022

Last Update Submit

March 22, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • Live birth incidence per serum βHCG value

    Compare the incidence of Live Birth according to serum βHCG (IU/L) measurement in all patients undergoing ART procedures.

    1 year

Secondary Outcomes (1)

  • Comparison of live birth incidence with serum βHCG confounders

    1 year

Study Arms (1)

IVF patients: first serum βHCG

IVF patients who undergo βHCG after fresh or frozen embryo transfer

Behavioral: Prompt diagnois pregnancy outcome

Interventions

IVF patients: first serum βHCG

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

The study will include retrospectively all patients that underwent IVF cycles (including fresh and thawed embryo transfers) between January 2011 and December 2020 at a Third level University-affiliated center, Humanitas Fertility Center in (Rozzano, MI). The internal database (Art-it) will be used to retrieve data on age, body mass index (BMI), baseline sex hormone levels, main causes of infertility, endometrial thickness, details of stimulation protocols, date of insemination, date of embryo transfer, number of embryos transferred, date of βHCG examination, serum concentrations of βHCG, fertilization results, pregnancy types (EP, biochemical pregnancy, intrauterine)

All women that underwent IVF cycles (including fresh and thawed embryo transfers) between January 2011 and December 2020.

Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.

Sponsors & Collaborators

Related Publications (2)

  • Seeber BE, Sammel MD, Guo W, Zhou L, Hummel A, Barnhart KT. Application of redefined human chorionic gonadotropin curves for the diagnosis of women at risk for ectopic pregnancy. Fertil Steril. 2006 Aug;86(2):454-9. doi: 10.1016/j.fertnstert.2005.12.056. Epub 2006 Jun 6.

    PMID: 16753158BACKGROUND
  • Wang Z, Gao Y, Zhang D, Li Y, Luo L, Xu Y. Predictive value of serum beta-human chorionic gonadotropin for early pregnancy outcomes. Arch Gynecol Obstet. 2020 Jan;301(1):295-302. doi: 10.1007/s00404-019-05388-2. Epub 2019 Nov 22.

Study Officials

  • Paolo Emanuele Levi Setti, MD

    Istituto Clinico Humanitas

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD, Research Administration Manager and Head of Clinical Trial Office Humanitas Clinical and Research Center

Study Record Dates

First Submitted

February 3, 2022

First Posted

March 31, 2022

Study Start

January 1, 2011

Primary Completion

December 31, 2020

Study Completion

December 31, 2020

Last Updated

March 31, 2022

Record last verified: 2022-03

Data Sharing

IPD Sharing
Will not share